A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future ...

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.

The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community health centre in London, Health Secretary Wes Streeting ...

Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.

The UK Government is pushing for a single, unified digital patient record within the NHS, but experts have shared cybersecurity concerns.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software feels like it’s changing faster than you can read it. They’re emphasizing ...

Dizal has received FDA approval for Zegfrovy to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the ...

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.